Linda Montgomery • January 10, 2024
Trial Participation- There is still time to join!

HCM Clinical Trial Opportunities 

We’ve been urging you to learn a few important points about your disease because HCM has various presentations and important metrics.

  • Are you obstructed or non-obstructed?
  • What is your Ejection Fraction – (EF)?
  • What is your NYHA functional class?
  • If you have a genetic mutation, if so, what is it?

Knowing the answers to these questions gives a healthcare provider a snapshot of your disease and also facilitates eligibility for clinical trials.  

Current trials:

  • The first is the Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy (ODYSSEY-HCM). For more information, please complete this survey: https://www.surveymonkey.com/r/pulse3
  • Other myosin inhibitor trials regarding the Efficacy and Safety of Aficamten. For information about this and other trials, please complete the survey: https://www.surveymonkey.com/r/pulselet6
  • MyPeak-1 is actively enrolling patients with nonobstructive HCM who have the MYBPC3 genetic mutation. For more information, please complete this survey: https://www.surveymonkey.com/r/peak10
  • For our younger HCM community members with the MYBPC3 gene, a study: Natural History Study in Pediatric Patients With MYBPC3 Mutation-associated Cardiomyopathy (MyCLIMB ).

If you are interested in any of these trial opportunities, please send me an email with your contact information – my email is linda@4hcm.org. 

If you haven’t gone through the HCMA Intake process within the last two years, please schedule an Intake Call on the website https://4hcm.org/education-and-support/. 

This will give us the best understanding of your current health, HCM presentation, and potential eligibility in upcoming trials.

HCMA Blog

A light blue and dark blue paintbrush stroke intersect to make a stylized

Alnylam Receives European Commission Approval for AMVUTTRA® (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy (ATTR-CM)

By Erica Friedman • June 18, 2025
Alnylam press release on the European Commission approval of AMVUTTRA® (vutrisiran) forwild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM) as an additional indication
Light & dark blue brush stroke that intersect create an abstract letter 'a' next to the word Alnylam

Alnylam Announces FDA Approval of AMVUTTRA® (vutrisiran) for Adults with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM)

By Erica Friedman • June 17, 2025
AMVUTTRA® (vutrisiran) has been approved by the U.S. Food and Drug Administration (FDA) to treat ATTR-CM in adults.
A pregnant woman and partner make a heart with their hands over the baby.

HCM in Pregnancy

By Sabrina Cuddy • June 12, 2025
Pregnancy is a stress on the body even for healthy people. When we have a serious disease, we tend to have even more questions. Health Educator Sabrina Cuddy answers some of the most common questions about HCM and Pregnancy.
More Posts